Delving into the Latest Updates on Goldenmed Biotechnology with Synapse

概览

关联

1

项与 Goldenmed Biotechnology 相关的药物

DCB-BO-1202

靶点-

作用机制-

在研机构-

原研机构

Goldenmed Biotechnology

在研适应症-

非在研适应症

肝纤维化 [+3]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 Goldenmed Biotechnology 相关的临床试验

NCT02289300 / Withdrawn临床2期

A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies

The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)

开始日期2020-01-01

申办/合作机构

台湾A2医疗保健股份有限公司

[+1]

100 项与 Goldenmed Biotechnology 相关的临床结果

登录后查看更多信息

0 项与 Goldenmed Biotechnology 相关的专利（医药）

登录后查看更多信息

100 项与 Goldenmed Biotechnology 相关的药物交易

登录后查看更多信息

100 项与 Goldenmed Biotechnology 相关的转化医学

登录后查看更多信息